Emily Minkow

Emily Minkow is a seasoned professional in the biotechnology and pharmaceuticals sectors, currently serving as a Venture Partner at RA Capital Management, L.P. since January 2022. Previously, Emily held the position of Interim CEO at Stylus Medicine from September 2022 to February 2024, and before that, served as Chief Business Officer and Executive Vice President of Business Development and Strategy at Prevail Therapeutics from November 2017 to March 2021. Emily's earlier experience at Celgene spanned various roles, including Executive Director and Senior Director of Business Development, and Director of Global Marketing for Otezla. Emily began their career as a Consultant at The Frankel Group from 2006 to 2008. Educational credentials include an MBA from Harvard Business School and an AB in Public and International Policy from Princeton University.